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Abstract
Background. Registration of infliximab in Poland has increased chances to induce clinical remission and 
mucosal healing in the severe form of pediatric Crohn’s disease.
Objectives. The aim of this retrospective study was to assess the results and safety of infliximab therapy in 
the severe form of pediatric Crohn’s disease.
Material and methods. The study included 153 children with severe form of non-fistulizing Crohn’s 
disease treated with infliximab. The clinical activity of Crohn’s disease was assessed according to PCDAI 
scale, endoscopic scoring was graded according to SES-CD, body mass was measured with body mass index 
(BMI). Infliximab was administered at the dose 5 mg/kg body mass in the 0.2 and 6th week, and then, after 
clinical response, every 8 for the period of 12 months.
Results. One hundred thirty-six children (88.89%) achieved clinical response after induction therapy and 
75.21% of children after the maintenance therapy. 39.68% of children achieved remission as graded with 
endoscopic scoring SES-CD. There was a statistically significant increase in body weight following the treat-
ment. Side effects such as anaphylaxis, rash, and the activation of EBV infection appeared in 9 children at 
the time of infliximab injection. In other children the drug was well tolerated.
Conclusions. Induction and maintenance therapy with infliximab resulted in clinical remission of Crohn’s 
disease in 75.21% of children, and in the intestinal mucosa healing in 39.68% of children.
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Crohn’s disease (CD) and ulcerative colitis (UC) are clas-
sified as inflammatory bowel diseases of unknown etiol-
ogy and with no causative treatment. Increased incidence 
of pediatric Crohn’s disease together with the constant in-
cidence of ulcerative colitis has been observed during the 
last decade.1 Crohn’s disease may be diagnosed in people 
of all age groups, but most frequently in children over the 
age of 10 years, with its peak incidence occurring between 
15–40 years of age. In 25–30% of patients first symptoms 
appear under the age of 20 years.1,18,20 In Crohn’s disease, 
inflammatory changes affect full thickness of the bowel 
wall and occur segmentally with locations that can affect 
all parts of the gastrointestinal tract from mouth to rec-
tum. The disease course is more severe in children than in 
adults. Crohn’s disease is characterized by greater exten-
sion of intestinal lesions, higher incidence of exacerbations, 
fistulas and perianal changes, inhibited physical and sexual 
development, loss of body weight and malnutrition.7,21,23 
The primary goal of Crohn’s disease treatment is to obtain 
clinical remission and mucosal healing, physical develop-
ment and improvement of the quality of life and the nor-
malization of biochemical parameters including the fecal 
calprotectin determination.20 Patients are treated with 
5-ASA  preparations, thiopurine, glucocorticoids, nutri-
tional preparations, antibiotics, biological agents and sur-
gical treatment. Recent guidelines regarding the induction 
therapy of mild-to-moderate Crohn’s disease recommend 
nutritional therapy, steroids, antibiotics and biopharma-
ceuticals; whereas in the maintenance therapy thiopurine, 
methotrexate, and biological therapy are recommended.20 
Early immunosuppressive and biological therapies should 
be introduced in children that have a  high risk of suffer-
ing a severe course of the disease which includes: very early 
age of onset, the presence of deep ulcerations in endoscopic 
examination, inflammatory changes in the upper gastroin-
testinal tract, rectum and entire colon, growth delay, severe 
osteoporosis and the presence of fistulas.20
The  aim of this study was to present a  retrospective 
evaluation of effects and safety of infliximab therapy in 
the severe form of pediatric Crohn’s disease.
Material and methods
To  assess the effects of treatment with inflixamib the 
authors have invited university pediatric gastroenterology 
centers and pediatric departments in regional hospitals 
in Poland, which treated pediatric Crohn’s disease in the 
years 2004–2013. Each center received a personal ques-
tionnaire for the biological treatment which included the 
patient’s age, sex, body mass index (BMI), location and 
manifestation of disease activity, pharmacological, nutri-
tional, and surgical treatment, inductive and maintenance 
effects of biological therapy with infliximab. The diagno-
sis of Crohn’s disease was based on Porto criteria.11 How-
ever, the location and manifestation of the disease were 
assessed based on the Paris Classification.15 The  inclu-
sion criteria for the pediatric infliximab treatment was 
a severe, active form of Crohn’s disease measured by the 
Pediatric Crohn’s Disease Activity Index (PCDAI) above 
50 pts., the absence of clinical response to previous treat-
ment with corticosteroids, immunosuppressants and nu-
tritional treatment.8,12 Infliximab was used in the induc-
tion treatment at a dose of 5 mg/kg in the 0.2 and 6th week 
after the first intravenous infusion. Maintenance inflix-
imab therapy was administered to patients with clinical 
response, i.e. reduced disease activity by < 12.5 points (or 
more) and PCDAI level below 30 pts. for at least 2 weeks 
after the third dose of infliximab at doses: 5 mg/kg every 
8 weeks (6 doses), together with the induction therapy for 
the period of 12  months. Clinical remission in Crohn’s 
disease is defined as its activity after the maintenance 
treatment amounting to ≤ 10 points in the PCDAI scale. 
The endoscopic activity of the disease was scored before 
and after the maintenance treatment with infliximab ac-
cording to SES-CD (Simplified Endoscopic Activity Score 
for Crohn’s Disease). Mucosal healing was defined as 
0 pts. according to SES-CD.3
In  the years 2004–2013, 424  children in Poland were 
treated with infliximab.12 Two hundred twenty one (221) 
completed questionnaires from 10  health-care institu-
tions were submitted in order to assess the results of the 
treatment of pediatric Crohn’s disease. Two hundred 
eight (208) children were qualified. Out of this number, 
153 children were diagnosed with non-fistulizing Crohn’s 
disease, whereas 55 were diagnosed with fistulizing 
Crohn’s disease. Thirteen patients provided in their ques-
tionnaires incomplete clinical data and, therefore, they 
were not included in the final evaluation of treatment 
(Table 1). In this study the authors have assessed only the 
effects of treatment with infliximab in 153 children with 
non-fistulizing Crohn’s disease. The effects of treatment 
of 55 children with fistulizing Crohn’s disease are going to 
be developed separately.
The results were statistically analyzed. Basic descriptive 
statistics were calculated as an arithmetic mean (x), stan-
dard deviation (SD), median. The authors have compared 
results of clinical (PCDAI) and endoscopic (SES-CD) ac-
tivity, BMI (body mass index) before treatment and 1 year 
after treatment with the Student’s t-test for dependent 
samples. The authors have also calculated the correlation 
Table 1. Number of children with Crohn’s disease in Poland treated with 
infliximab in the years 2004–2013
Total number of treated children 424
The number of received questionaires treated  
with infliximab 221 (52.12%)
To the assessment of infliximab therapy were 
qualified
a) Crohn’s disease without fistulas
b) Crohn’s disease with fistulas
c) incomplete data
153 (69.23%)
 55 (24.89%)
13 (5.88%)
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between PCDAI, SES-CD, BMI with Pearson’s correlation 
coefficient. Results were considered to be statistically sig-
nificant at p < 0.05.
The study was approved by the Bioethical Committee of 
Wroclaw Medical University.
Results
Characteristics of pediatric patients have been present-
ed in Table 2. Crohn’s disease was most frequently diag-
nosed in children between 10–17 years of age (77.83%). 
Very young children under the age of 5 years accounted for 
4.52% of patients, children between 6–10 years of age ac-
counted for 17.65% patients. The disease duration ranged 
from 1–84 months, with a mean of 25 months. In 7 cases 
(3.16%) Crohn’s disease or ulcerative colitis were diag-
nosed in a patient’s sibling or a parent. Parenteral mani-
festation of Crohn’s disease was observed in 31 patients 
(14.03%), and that was most commonly anemia, arthral-
gia, erythema nodosum, osteopenia; whereas 23 children 
(10.4%) were diagnosed with other co-morbidities.
Location of inflammation in Crohn’s disease has been 
presented in Table 3. Its most frequent location was ter-
minal ileum and colon (42.97%), colon 14.03%, in 1/3 dis-
tal ileum (13.12%). Inflammation was often accompanied 
by changes in the upper gastrointestinal tract. Manifes-
tation of Crohn’s disease has been presented in Table 4. 
In 128 children (57.92%) Crohn’s disease was inflamma-
tory, non-stricturing and non-penetrating, in 38 children 
(17.19%) structuring, in 37 children (16.74%) penetrating, 
and in 18  children (8.14%) stricturing and penetrating. 
Fifty-five (24.88%) children were diagnosed with fistuliz-
ing Crohn’s disease. Forty (18.1%) children suffered from 
growth retardation (Table 4).
The effects of induction treatment in 153 children have 
been presented in Table 5. Clinical response occurred in 
136  children (88.89%) after 3 doses of infliximab; clini-
cal improvement has not been observed in 14  children 
(9.15%); in 3 children (1.96%) treatment has been discon-
tinued due to the anaphylactic shock that occurred dur-
ing the administration of the second (2 children) and third 
dose of infliximab (1 child).
The effects of the maintenance treatment were evaluat-
ed in 117 children; 36 children did not qualify for further 
maintenance treatment: 14 children due to lack of clinical 
response following the induction therapy, 3 children due 
to the anaphylactic shock. Nineteen patients over the age 
of 18 years were transferred for further biological therapy 
in gastroenterology departments for adults.
The  effects of maintenance treatment have been pre-
sented in Table  6. Clinical remission has been achieved 
in 88 (75.21%) children, endoscopic remission (0 pts. in 
SES-CD scale) has been achieved in 25 out of 63 children 
(39.68%). Eighteen children experienced exacerbated 
clinical symptoms during the maintenance therapy and 
8 children (6.84%) required surgical treatment. Relapse of 
Table 2. Characteristics of the children with Crohn’s disease treated with 
infliximab
Assessed parameter
Number of children
n %
Sex:  male
 female
118
103
53.39
46.60
Age at diagnosis (years) < 5  10  4.52
6–10  39 17.65
11–17 172 77.83
IBD in family   7  3.16
Concomitant disorders  23 10.40
Extraintestinal symptoms  31 14.03
n – number.
Table 3. Localization of Crohn’s disease in 221 children treated with 
infliximab
Location
Number of children
n %
L1 distal 1/3 ileum  29  13.12
L2 colonic  31  14.03
L3 ileocolonic  95  42.97
L4 upper disease   2   0.91
L1 + L4  14   6.34
L2 + L4  15  6.79
L3 + L4  35  15.84
Total 221 100.00
Table 4. Clinical manifestation of Crohn’s disease in 221 children treated 
with infliximab
Behavior of Crohn’s disease
Number of children
n %
B1 non-stricturing, non-penetrating 128 57.92
B2 stricturing  38 17.19
B3 penetrating  37 16.74
B4 stricturine and penetrating  18  8.14
P fistulas perianal
other
 50
  5
22.62
 2.26
G0 no evidence of growith delay 181 81.90
G1 growth delay  40 18.10
Table 5. Results of induction therapy in 153 children with Crohn’s disease 
without fistulas
Clinical assessment n %
Clinical response 136  88.89
Lack of response  14   9.15
Anaphylactic stock   3   1.96
Total 153 100.00
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disease occurred after 1 year of treatment in 18 out of 70 
(25.71%) children, 9 of whom were again subjected to the 
biological treatment (Table 6).
In Table 7, the authors have compared the results of PC-
DAI, SES-CD and BMI before and after one-year therapy 
with infliximab. The  authors have reported significantly 
reduced clinical (PCDAI) and endoscopic (SES-CD) activ-
ity of Crohn’s disease and statistically significant increased 
body weight (BMI). However, a comparison of the relation-
ship between measured parameters has shown, with the 
Pearson correlation coefficient, a  statistically significant 
correlation between PCDAI and SES-CD before (r = 0.24, 
p = 0.037) and after the treatment (r = 0.4, p = 0.001). Side 
effects such as anaphylaxis, rash, activation of EBV infec-
tion, increased blood pressure and tachycardia occurred 
in 9  children during intravenous infliximab infusion 
(Table 8). Infliximab was well tolerated in other children. 
During the treatment patients also received preparations 
of 5-ASA, azathioprine or methotrexate.
Discussion
Crohn’s disease is a chronic inflammation of intestines 
characterized by a progressive course with periods of re-
mission and exacerbation. The  natural course of disease 
is characterized by inflammation of the intestinal mu-
cosa that gradually covers layers of intestinal walls and 
leads to fibrosis, stenosis and to the development of fis-
tulas. The course of the disease is more severe in children 
compared to adults, since lesions are more extensive, and 
there occur disturbances in growth and puberty; paren-
teral symptoms complications and surgical interventions 
appear more often.6,21 It is assumed that early onset of the 
disease increases the possibility of its severe progressive 
course. Diagnosis of severe Crohn’s disease in children 
under the age of 5 years may be associated with genetic 
disorders5,15 Disorders of IL-10 mutation or its receptor, as 
well as other genetic disorders6,15,18,20 have been reported 
in the youngest children. The authors have reported that 
Table 6. Results of induction and maintenance therapy with infliximab of 117 children with Crohn’s disease after 54 weeks of the treatment
Results of therapy
Number of children
n %
Clinical remission 88 75.21
Endoscopic remission 25/63 39.68
Exacerbation of the disease during treatment 18 15.39
Anaphylactic shock (after 4th and 6th dose)  3  2.56
Surgical treatment  8  6.84
Reccurence of the disease before one year after the end of treatment 18/70 25.71
New treatment:
• infliximab
• adalimumab
6/18
3/18
35.29
16.66
Table 7. Comparison of clinical activity (PCDAI), endoscopic activity (SES-CD) and BMI before (I) and after one year (II) infliximab treatment
Assessed
parameter
No. of
children
Results
I (before treatment) II (one year after treatment)
p
x medina range SD x medina range SD
PCDAI 78 57.66 55 52–85 6.65  9.39 5 0–62.5 14.36 < 0.001
SES-CD 61 14.51 12 1–39 9.9  5.32 3 0–32  7.24 < 0.001
BMI (kg/m2) 78 17.37 17.05 13.0–30.5 2.91 19.23 20.05 15.80–33.12  2.37 0.008
x – mean; SD – standard deviation.
Table 8. Adverse events in children with Crohn’s disease treated with infliximab
Adverse symptoms
Only induction therapy 
(36 children)
Induction and maintenance 
therapy (117 children) Total (153 children)
n % n % n %
Anaphylactic shock 3 8.33 3 2.56 6 3.92
Generalized rush 1 0.85 1 0.65
EBV infection activation 1 0.85 1 0.65
Increase of blood pressure and tachycardia 1 0.85 1 0.65
Total 3 8.33 6 5.13 9 5.88
Adv Clin Exp Med. 2017;26(1):51–56 55
Crohn’s disease was most frequently diagnosed in children 
over 10 years of age (77.83%). Children under 5 years of age 
accounted for 4.52%, and aged 6–10 years for 17.65% (39) 
of all respondents. More boys were sick compared to girls 
(53.39% vs. 46.60%). These results are consistent with what 
other authors have reported.1,20
5-ASA preparations, glucocorticoids, immunomodula-
tors, nutritional therapy, antibiotics, anti-TNF-α prepara-
tions and surgical treatment are used in Crohn’s disease 
treatment. These are non-specific anti-inflammatory 
drugs. They inhibit the formation and the release of in-
flammatory mediators, reduce the number of cells and in-
hibit the activity of a body’s defense cells. Corticosteroids 
are characterized by rapid onset of action and the induc-
tion of clinical remission. In mild-to-moderate activity of 
pediatric Crohn’s disease with the ileocaecal location to 
induce remission, topical budesonide, rather than system-
ic glucocorticosteroids treatment, can be administered. 
However, corticosteroids should not be used in therapy 
that maintains disease induction, because they do not 
lead to mucosal healing. Azathioprine, 6-mercaptopu-
rine and methotrexate are important drugs maintaining 
disease remission. Preparations of 5-ASA should be used 
only in patients with a very mild form of Crohn’s disease.20 
Methotrexate is recommended in maintenance treatment 
of children with a severe course of disease with unfavor-
able prognostic factors following unsuccessful thiopurine 
therapy.20
Recently, the main goals of treatment have changed. 
Currently, the primary objective of treatment is not only 
clinical remission, improved nutrition, growth and quality 
of life, but above all, induction of mucosal healing, i.e. deep 
mucosal remission (DR-deep remission).20 These results 
can be achieved with the total enteral nutrition (exclu-
sive enteral nutrition – EEN) for the period of 6–8 weeks, 
with thiopurines or biological therapy.20 Different types of 
the treatment mentioned above have been administered 
to children. Due to the relapse of disease or the lack of 
improvement after the treatment and the severe active 
course of the disease, children with the PCDAI scale ac-
tivity exceeding 50 pts. were included in the biological 
therapy with infliximab. Infliximab is the first biological 
drug approved by the US Food and Drug Administration 
(FDA), and then it got approval in Europe and Poland for 
the treatment of Crohn’s disease and ulcerative colitis. 
Infliximab is an IgG1 monoclonal antibody directed 
against tumor necrosis factor (TNF-α-Tumor Necro-
sis Factor). It is a human-mouse chimeric antibody with 
high affinity to both soluble and trans-epithelial form of 
TNF-α. Infliximab has been approved in Poland for the 
treatment of severe active form of pediatric Crohn’s dis-
ease (PCDAI > 50 pts.) in patients aged 6–17 years, not 
subjected to typical treatment, or after the presence of 
contraindications or intolerance symptoms or resistance 
to used medications.12 As this study has shown, infliximab 
was also, following the consent of the regional Bioethics 
Committees, used in the youngest children with severe 
course of disease despite registration recommendations.
Many studies have demonstrated the efficacy of biological 
therapy, thiopurines, nutritional therapy both in the induc-
tion and in maintaining remission, and in the mucosal heal-
ing.2,4,5,7,9,10,13,16,17,22 D’Haens et al.17 have reported that treat-
ment with infliximab and azathioprine is more effective in 
inducing mucosal remission compared to glucocorticoid.17 
Another study has proven that treatment with infliximab 
in combination with azathioprine is much more effective 
compared to treatment with azathioprine only, and patients 
with the mucosal healing required fewer hospitalizations 
and surgical treatment.2,16,20 Treatment with infliximab in 
the induction and in maintaining remission has been ef-
fective. Height gain and the possibility to reduce cortico-
steroids doses could be observed in patients. In  the 54th 
week of treatment infliximab was more effective at a dose 
of 5 mg/kg every 8 weeks than every 12 weeks. Hyams et al. 
confirmed the efficacy of infliximab treatment in the course 
of a 3-year follow-up.10 Withdrawal of glucocorticoids was 
possible in most children. Ruemmele et al. in their studies 
confirmed clinical efficacy, tolerability and the safety of in-
fliximab.19 They achieved clinical remission in 83% of chil-
dren using intravenous infusions every 8  weeks. Kierkuś 
et al. have demonstrated the efficacy of infliximab in clinical 
remission and mucosal healing in children. Assessing re-
sults of induction therapy with infliximab in 66 children in 
the 10th week of the treatment, the authors have achieved 
clinical remission in 33%, clinical response in 39%, and mu-
cosal healing in 22.7%. Only 28% children did not respond 
to treatment with infliximab. In another study, the authors 
have analyzed results of treatment with infliximab main-
taining the clinical remission with or without azathioprine. 
They have not obtained statistically significant differences 
in maintenance treatment between the two groups of sick 
children.14
These results are comparable to the results from other 
studies. Following one year of infliximab therapy, the au-
thors received clinical remission in 75.21% of children, 
and endoscopic remission in 39.68% of children. More-
over, the nutritional status of children has improved and 
statistically significant weight gain has been reported fol-
lowing one year of therapy with infliximab. Infliximab 
was generally well tolerated. Side effects such as anaphy-
laxis, urticaria, and activation of EBV infection appeared 
in 5.88% of children. In the remaining children, the drug 
was well tolerated.
Despite prior ineffective immunosuppressive therapy, 
the authors proved the efficacy of induction therapy and 
the infliximab therapy maintaining remission of the dis-
ease in the treatment of severe pediatric Crohn’s disease. 
Apart from clinical remission of disease, the authors have 
reported mucosal healing, improvement in nutritional 
status, and, thus, better quality of life of pediatric patients. 
Infliximab was safe and well tolerated in the majority of 
them.
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